Lv61
1680 积分 2022-11-01 加入
Obesity drugs aren’t always forever. What happens when you quit?
1个月前
已完结
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
1个月前
已完结
Anti-obesity drugs’ side effects: what we know so far
1个月前
已完结
Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy
1个月前
已关闭
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
1个月前
已完结
Association between systemic medication use and severity of dry eye signs and symptoms in the DRy eye assessment and management (DREAM) study
1个月前
已完结
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease
2个月前
已完结
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial
2个月前
已完结
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension
2个月前
已关闭
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial
2个月前
已关闭
皖公网安备34019202002308
